Feasibility Clinical Trial of the Cardio Flow Orbital Atherectomy System to Treat Peripheral Artery Disease (PAD) (FAST)

Feasibility Clinical Trial of the Cardio Flow FreedomFlow Orbital Atherectomy System to Treat Peripheral Artery Disease

This trial is a First in Human early feasibility study of a novel atherectomy device to treat peripheral artery disease. The trial is a prospective, single arm design that will enroll 10 patients at 1 - 2 sites. Patients will be followed at 30 days and 6 months to evaluate vessel patency following treatment. Safety will be assessed by monitoring adverse events throughout the study. Safety and Efficacy will be evaluated by comparing study results to established performance criteria,

Study Overview

• Status: Completed
• Conditions: Peripheral Arterial Disease
• Intervention / Treatment: Device: Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment; Device: Balloon Angioplasty

Detailed Description

Feasibility Clinical Trial of the Cardio Flow FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease (FAST Trial) is a prospective non-randomized single arm study that will enroll up to 10 patients at 1 - 2 sites. The study will evaluate the safety and effectiveness of the Cardio Flow atherectomy device for plaque removal in de novo target lesions in the peripheral vasculature of the lower extremities. The primary safety endpoint is defined as freedom from a composite of new onset major adverse events through the 30-day follow-up as adjudicated by an independent Clinical Events physician. The primary effectiveness endpoint is defined as the ability of the Cardio Flow Device to achieve a residual diameter stenosis ≤ 50% without adjunctive therapy, determined by Angiographic core lab evaluation.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Florida
    • Gainesville, Florida, United States, 32605
      • Cardiovascular Research of North Florida, LLC
  • Michigan
    • Saint Clair Shores, Michigan, United States, 48080
      • Eastlake Cardiovascular, PC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Candidate for percutaneous endovascular intervention in the lower extremity;
• Disease is located in peripheral arteries between 2mm and 5mm diameter;
• Ankle brachial index ≤ 0.90;
• Rutherford classification 2,3,4 or 5;
• De novo target lesion has ≥ 50% stenosis;
• Target lesion length ≤ 200 cm;
• At least 1 patent tibial vessel runoff;
• Written, signed informed consent.

Exclusion Criteria:

• Female not using adequate contraception or is breastfeeding;
• Rutherford class 0 1, and 6;
• target lesion within a native graft,
• in-stent restenosis,
• ≤ 50% occlusion, or chronic total occlusion;
• history of vascular surgery or interventional procedure on index limb within 30 days prior to procedure, or planned procedure within 30 days after index procedure, lesion in contralateral limb requiring intervention during index procedure or within 30 days of index procedure;
• known or suspected systemic infection;
• unstable coronary disease; significant kidney disease requiring dialysis;
• evidence of aneurysmal target vessel within past 2 months;
• evidence of intracranial or GI bleeding, intracranial aneurysm, MI or stroke within 2 months of baseline evaluation;
• history of heparin-induced thrombocytopenia;
• contraindication to anti-platelet, anticoagulant, or thrombolytic therapy;
• uncorrected bleeding disorders;
• thrombolytic therapy within 2 weeks of index procedure;
• life expectancy less than 12 months;
• unwilling or unable to comply with follow-up requirements;
• intraoperative complications due to the use of a marketed device prior to use of the atherectomy system;
• currently participating in an investigational drug or other device study that has not completed primary endpoint;
• unable to tolerate standard interventional procedures if the study device is not effective.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Treatment Group; Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.	Device: Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment; Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.; Other Names: Orbital Atherectomy Treatment; Device: Balloon Angioplasty; Low pressure balloon angioplasty may be used following atherectomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Treated Lesions With Achievement of ≤ 50% Residual Stenosis Without Adjunctive Therapy	Achievement of ≤ 50% residual stenosis without adjunctive therapy as assessed angiographically on a per lesion basis	At time of procedure
Number of Participants Who Were Free From New-onset Major Adverse Events at 30 Days Post-treatment	Major adverse events include the following: All cause cardiovascular mortality.; Myocardial infarction (MI): Any newly diagnosed MI post procedure, defined as CK-MB ≥2X upper limit normal (ULN).; Clinically driven target lesion revascularization (TLR): any repeat percutaneous or surgical intervention to treat objectively documented symptoms of recurrent ischemia attributable to the treated lesion.; Clinically significant target vessel dissection: NHLBI grade C or greater as confirmed by angiography.; Clinically significant target vessel perforation: NHLBI Type III as confirmed by angiography.; Unplanned major target limb amputation: Amputation at the level of the trans-metatarsals or higher that was not previously planned; Clinically relevant distal embolization: Emboli requiring surgical or medical intervention and/or the presence of symptoms.; Pseudoaneurysm: disruption of the arterial wall at the treatment site as confirmed by angiography.	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serious Adverse Events	All device and procedure related Serious Adverse Events at 30 days and 6 months	Through six months
Number of Lesions With Achievement of ≤ 50% Residual Stenosis With or Without Adjunctive Low-pressure Balloon Therapy	Ability to achieve <50% residual diameter stenosis with or without adjunctive low-pressure balloon therapy on a per-lesion basis. Operator can follow atherectomy treatment with adjunctive balloon therapy.	At time of procedure

Collaborators and Investigators

• Sponsor: Cardio Flow, Inc.
• Collaborators: Libra Medical
• Investigators: Study Director: Phil Zang, MD, Libra Medical

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 25, 2018
• Primary Completion (ACTUAL): February 22, 2018
• Study Completion (ACTUAL): November 6, 2018

Study Registration Dates

• First Submitted: December 1, 2017
• First Submitted That Met QC Criteria: December 5, 2017
• First Posted (ACTUAL): December 7, 2017

Study Record Updates

• Last Update Posted (ACTUAL): May 20, 2021
• Last Update Submitted That Met QC Criteria: April 29, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Keywords: Peripheral Artery Disease; Orbital Atherectomy; Atherectomy
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Atherosclerosis; Peripheral Arterial Disease; Peripheral Vascular Diseases
• Other Study ID Numbers: 010-031

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Descriptive statistics of primary and secondary endpoints may be shared.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes